Dr. Kwa on the Potential Impact of Biosimilars in Oncology

Maryann J. Kwa, MD
Published: Tuesday, Jun 26, 2018



Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the potential impact of biosimilars in oncology.

There is a lot of motivation in the field of oncology to decrease costs, says Kwa. Biosimilars can provide the medications that are easily accessible in the United States to other countries around the world that may not have access to the same standard of care. Biosimilars will soon become very important in reducing healthcare costs around the globe, explains Kwa.

Although filgrastim-sndz (Zarxio), a biosimilar for the G-CSF analog filgrastim (Neupogen), is the only biosimilar commonly used in oncology practice, Kwa is hopeful that more biosimilars will be adopted in the United States.

MYL-1401O (Ogivri; trastuzumab-dkst) is currently the only trastuzumab (Herceptin) biosimilar approved by the FDA. The biosimilar is indicated for HER2-positive patients with breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma, which are the same indications as trastuzumab. 


Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the potential impact of biosimilars in oncology.

There is a lot of motivation in the field of oncology to decrease costs, says Kwa. Biosimilars can provide the medications that are easily accessible in the United States to other countries around the world that may not have access to the same standard of care. Biosimilars will soon become very important in reducing healthcare costs around the globe, explains Kwa.

Although filgrastim-sndz (Zarxio), a biosimilar for the G-CSF analog filgrastim (Neupogen), is the only biosimilar commonly used in oncology practice, Kwa is hopeful that more biosimilars will be adopted in the United States.

MYL-1401O (Ogivri; trastuzumab-dkst) is currently the only trastuzumab (Herceptin) biosimilar approved by the FDA. The biosimilar is indicated for HER2-positive patients with breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma, which are the same indications as trastuzumab. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
Community Practice Connections™: Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic MalignanciesMar 08, 20193.0
Publication Bottom Border
Border Publication
x